SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-20-012198
Filing Date
2020-02-07
Accepted
2020-02-07 06:12:41
Documents
1
Group Members
DAVID L. DOUGLASSDEEPIKA R. PAKIANATHANDELPHI BIOINVESTMENTS VIII, L.P.DELPHI MANAGEMENT PARTNERS VIII, L.L.C.DOUGLAS A. ROEDERJAMES J. BOCHNOWSKI

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D/A tm206744-2_sc13d.htm SC 13D/A 129107
  Complete submission text file 0001104659-20-012198.txt   130805
Mailing Address 160 BOVET RD, SUITE 408 SAN MATEO CA 94402
Business Address 160 BOVET RD, SUITE 408 SAN MATEO CA 94402 650-854-9650
DELPHI VENTURES VIII LP (Filed by) CIK: 0001436285 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080
Business Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080 650-870-1000
Calithera Biosciences, Inc. (Subject) CIK: 0001496671 (see all company filings)

IRS No.: 272366329 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88349 | Film No.: 20584462
SIC: 2834 Pharmaceutical Preparations